- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Kansas AG accuses Pfizer of misrepresenting COVID vaccine, hiding safety risks in lawsuit | ||
| Di | Many overweight patients feel misunderstood by pharmas and not adequately represented in ads: survey | ||
| Di | Intra-Cellular's Caplyta scores again in major depressive disorder as blockbuster expansion comes within reach | ||
| Di | Lilly and Novo's brand values soar as GLP-1 drugs raise their profiles | ||
| Di | Merck's Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval | ||
| Di | AstraZeneca's Truqap misses the mark in late-stage triple-negative breast cancer trial | ||
| Di | Docs' zest for Skyrizi tees AbbVie up for fast ulcerative colitis launch | ||
| Di | Despite a strong pharma shortlist, only Biogen, Organon place in Cannes Pharma Lions, as med techs take Gold, Grand Prix | ||
| Mo | Merck gets shot in the arm with FDA approval for first pneumococcal vaccine designed for adults | ||
| Mo | Woes mount for Marinus with investor lawsuit, trial failure | ||
| Mo | From market withdrawal back to £3B peak sales: GSK dreams big for myeloma ADC Blenrep | ||
| Mo | India's Lupin announces CEO pick for new subsidiary as it moves into the CDMO arena | ||
| Mo | J&J to seek appeal of $150M verdict in long-spanning HIV meds off-label marketing case | ||
| Mo | AstraZeneca backs up Calquence's potential in mantle cell lymphoma with detailed data | ||
| Mo | AstraZeneca lands narrow Imfinzi nod in endometrial cancer. Where's Lynparza? | ||
| Mo | Novo Nordisk CEO Jorgensen agrees to testify before Senate over U.S. pricing of semaglutide products | ||
| Mo | France's LFB Biomanufacturing launches €20M cell production plant expansion | ||
| Mo | Havas forms GLP-1 consultancy to help clients manage disruption | ||
| Mo | Roche's Columvi win in earlier DLBCL faces questions over inconsistent patient survival data | ||
| Fr | Industry hails Supreme Court's decision to maintain mifepristone abortion pill's access | ||
| Fr | Takeda circles leukemia rival to Novartis' Scemblix in up to $1.3B deal with Ascentage | ||
| Fr | Vertex presents longer-term data that shows durability and consistency of Casgevy | ||
| Fr | Mission Based Media unveils ad-free model for health podcasts, including Eisai-backed Alzheimer's series | ||
| Fr | Bristol Myers bags FDA tumor-agnostic nod for Augtyro to challenge Bayer, Roche | ||
| Fr | Merck KGaA's MilliporeSigma devotes €62M to new quality control building in Germany |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
